ONO 2952

Drug Profile

ONO 2952

Alternative Names: ONO-2952

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ono Pharmaceutical
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action TSPO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 02 Feb 2016 Phase-II development is ongoing in USA
  • 16 Feb 2015 Ono Pharmaceutical terminates a phase II trial for Irritable bowel syndrome (Diarrhoea predominant) in USA (NCT01887002)
  • 01 Jul 2014 Ono Pharmaceutical completes the RESTORE phase II trial in Irritable bowel syndrome (Diarrhoea predominant) in USA (NCT01844180)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top